

CONTENTS

Chapter 1	The Framework for Regulation of Medical Devices	1
	The Impetus for Premarket Clearance of Medical Devices.....	1
	The Medical Device Amendments of 1976.....	3
	Definition of a Medical Device.....	3
	The Medical Device Reclassification Process.....	3
	The Classification System.....	3
	Class I: General Controls.....	4
	Class II: Performance Standards and Special Controls.....	4
	Class II: Performance Standards and Special Controls.....	4
	Classification of “Preamendment” Devices.....	5
	FDA’s Device Classification, 1973-1988.....	6
	Continuing Classification of Devices.....	7
	Marketing a Medical Device: Routes to Market.....	8
	510(k) Notification Process.....	9
	PMA Process.....	9
	PDP Process.....	9
	Reclassification.....	9
	De Novo Review (Automatic Reclassification) Following a Not Substantially Equivalent Determination.....	9
	General Principles of Market Clearance/Approval.....	10
	Reasonable Safety and Effectiveness.....	10
	Substantial Equivalence.....	12
	Considering Whether to File a 510(k) or PMA.....	12
	The Safe Medical Devices Act of 1990 and the Medical Device Amendments of 1992.....	13
	The SMDA.....	14
	User Reports.....	14
	Distributor Reports.....	14
	Device Tracking.....	14
	Substantial Equivalence to Preamendment Class III Devices.....	14
	Reclassification of Preamendment Class III Devices.....	14
	Transitional Devices.....	15
	Special Controls.....	15
	Performance Standards.....	15
	Reports of Removals and Corrections.....	15
	Recall Authority.....	15
	Temporary PMA Suspension.....	16
	Postmarketing Surveillance.....	16
	Use of Premarketing Approval Data.....	16
	Determining Substantial Equivalence.....	16
	Humanitarian Use Devices.....	16
	Office of International Relations.....	16
	Combination Products.....	17
	Civil Penalties.....	17
	Design Validation.....	17
	MDA 1992.....	17
	The Impact of the Food and Drug Administration Modernization Act of 1997 on the Approval Process.....	18
	Overriding Themes of the Legislation.....	18
	Investigational Device Exemptions.....	18
	Special Review for Certain Devices.....	19
	Expanding Humanitarian Use of Devices.....	19
	Device Standards.....	20

Scope of Review; Collaborative Determinations of Device	
Data Requirements	20
Premarket Notification	21
Evaluation of Automatic Class III Designation	22
Classification Panels	22
Certainty of Review Time Frames; Collaborative Review Process	23
Accreditation of Persons for Review of Premarket Notification	
Reports	23
Device Tracking	24
Postmarket Surveillance	24
Practice of Medicine	24
Use of Data Relating to Premarket Approval; Product Development	
Protocol	24
Dissemination of Information on “Off-Label” Uses	25
Mutual Recognition Agreements and Global Harmonization	25
MDUFMA 2002	25
User Fees	26
Performance Goals	26
Office of Combination Products	27
Modular PMA Reviews	27
Reprocessed Single Use Devices	27
Inspections by Accredited Third Parties	28
Manufacturer Identification	28
The Food and Drug Administration Amendment Act of 2007	28
User Fees	28
MDUFMA 2007 Substantial Changes	29
Pediatric Device Act	29
Reagan-Udall and Advisory Panels	30
Clinical Trial Registry	30
CDRH Organizational Structure	30
Office of the Center Director (OCD)	31
Office of Device Evaluation (ODE)	31
Office of Compliance (OC)	31
Office of Management Operations (OMO)	34
Office of Surveillance and Biometrics (OSB)	34
Office of Science and Engineering Laboratories (OSEL)	34
Office of Communication, Education, and Radiation Programs (OCER) ...	34
Office of In Vitro Diagnostic Device Evaluation and Safety (OIVD)	35

Chapter 2	The 510(k) Premarket Notification Process	37
	Premarket Notification: The Original Intent	38
	When Is a 510(k) Required?	39
	Misbranded/Adulterated Devices	40
	Definition of “Commercial Distribution”	40
	Determination of Preamendment Status	41
	Exemptions from Premarket Notification	42
	Exemptions of Generic Types of Class I Devices	42
	Exemptions of Generic Types of Class II Devices	49
	Custom Devices	51
	Other Exempt Devices	53
	Radiological Health	53
	Determination of Substantial Equivalence	54
	Congress Defines “Substantial Equivalence”	56
	Data Requirements for Substantial Equivalence	58
	Guidance Documents	59
	Collaborative Determinations of Device Data Requirements	60
	Clinical Trials	61

Table of Contents

Biocompatibility Issues	62
Preclinical Testing	66
Device Standards	67
Guidance on the Recognition and Use of Consensus Standards.....	68
Determination of Intended Use: Implied Intended Use and General/ Specific Intended Use.....	69
Regulatory Strategy Considerations.....	72
The Format and Content of a 510(k) Notice.....	72
Abbreviated 510(k) Notices	72
Basic Content Requirements and Format for Traditional and Abbreviated 510(k) Notices	73
Elements of a 510(k) Notice	74
Medical Device User Fee Cover Sheet (Form FDA 3601).....	74
CDRH Premarket Review Submission Cover Sheet.....	76
Indications for Use Statement	76
510(k) Summary or 510(k) Statement	76
The 510(k) Summary	78
The 510(k) Statement.....	84
Certification of the Truthfulness and Accuracy of the 510(k) Notice.....	84
Class III Summary and Certification.....	85
Financial Certification or Disclosure Statement	85
Declarations of Conformity and Summary Reports.....	85
Executive Summary.....	86
Device Description.....	87
Substantial Equivalence Discussion.....	87
Proposed Labeling	88
Sterilization and Shelf Life.....	88
Biocompatibility.....	88
Software.....	89
Electromagnetic Compatibility and Electrical Safety.....	89
Performance Testing: Bench	90
Performance Testing: Animal	90
Performance Testing: Clinical.....	90
Alternative Methods of Demonstrating Substantial Equivalence.....	91
Special Requirements for Kit 510(k)s.....	91
Bundling Multiple Devices or Indications in a Single Submission	92
Special Requirements for Single-Use Devices.....	92
FDA Review of 510(k) Notices	94
CDRH's Refuse to Accept 510(k) Notifications Policy.....	95
Requests for Additional Information and Interactive Review	97
Third-Party Review of 510(k)s	100
Accreditation of Persons.....	100
Third-Party Review Process.....	101
Termination of Third-Party Review Authority.....	101
The Advertising and Promotion of a Device Pending CDRH Clearance	102
FDA Actions Regarding Premarket Notifications	102
The Implications of a Finding of Substantial Equivalence.....	103
The Implications of a Not Substantially Equivalent Finding.....	103
Dispute Resolution	104
Judicial Review of a Substantial Equivalence Determination	106
510(k) Notice Review Times	106
Expedited Review	108
Determining the Status of CDRH's 510(k) Review	109
Linking GMP Inspections to Product Clearances	110

Medical Device Development: A Regulatory Overview

Chapter 3	Device Modifications Requiring a 510(k) Notice	113
	CDRH Policy on Device Modification	114
	The 510(k) Decision Flowchart.....	115
	Types of Device Modifications	120
	Design Creep/Changes	120
	Labeling Changes.....	121
	Technology/Manufacturing Changes.....	122
	Changes in a Device's Control Mechanism	123
	Changes in a Device's Operating Principle and Energy Source.....	123
	Changes in a Device's Sterilization Method	123
	Changes in a Device's Packaging.....	123
	Other Types of Changes.....	123
	Materials Changes	124
	Implantable Devices	124
	Non-Implantable Devices.....	125
	Changes to <i>In Vitro</i> Diagnostic Devices.....	126
	Changes to Wireless Telemetry Devices	127
	Changes to Recalled or Corrected Devices.....	128
	Impact of a Decision Not to File a New 510(k)	129
	The Special 510(k) Notice	133
Chapter 4	FDA Regulation of Medical Device Software	135
	Stand-Alone Information Management Software Devices	136
	Software as a Component or Accessory.....	137
	Review of Software Premarket Submissions	139
	Reviewer Guidelines	139
	Establishing the Level of Concern.....	140
	Major.....	141
	Moderate.....	141
	Minor	141
	Documentation of the Level of Concern.....	142
	Software Description.....	142
	Device Hazard Analysis.....	143
	Software Requirements Specification (SRS).....	144
	Traceability Analysis	144
	Verification, Validation, and Testing	145
	Results of Testing and Analysis.....	145
	Labeling	146
	Off-the-Shelf (OTS) Software.....	147
	Software Changes.....	152
	Telemedicine and PACS Devices	152
	Medical Device Software: The Future	153
Chapter 5	The Investigational Device Exemption Application: Overview of the IDE Process and Humanitarian Devices	155
	Responsibility for IDE Review	157
	Nonsignificant Risk Devices	158
	Exempted Investigations: Devices Exempted from IDE Requirements.....	158
	Preamendment Devices.....	159
	Substantially Equivalent Devices.....	159
	Diagnostic Devices	160
	Consumer Preference Testing.....	160
	Veterinary Use	160
	Laboratory Animal/Research Use	160

Table of Contents

Custom Device	160
Determination of Investigational Device Risk	161
Significant Risk (SR) vs. Nonsignificant Risk (NSR) Devices	161
Selection of the IRB.....	168
Planning for the IDE Application.....	169
CDRH Guidances Applicable to IDEs.....	170
The Pre-IDE Filing Meeting	171
FDAMA Early Collaboration Meetings.....	173
Agreement Meeting.....	173
Determination Meeting.....	173
Content of an IDE Application	175
CDRH Review of the IDE Application.....	178
CDRH's Refuse to Accept Policy.....	178
FDA Requests for Additional Information	180
FDA Actions Regarding IDE Applications	180
Confidentiality	181
Reimbursement for Investigational Devices	181
IDE Supplements.....	182
IDE Applications for Feasibility Studies	184
The Promotion and Commercialization of Investigational Devices	186
Expanded Access to Investigational Devices.....	189
Emergency Use	189
Compassionate Use	190
Treatment Use.....	190
Continued Access	191
Investigator-Sponsor Studies	192
Humanitarian Devices.....	192
Summary.....	196

Chapter 6 Medical Device Clinical Studies.....	197
History of Medical Device Clinical Studies.....	197
Clinical Trial Design Considerations.....	199
Number of Clinical Investigations Required for Approval	199
Developing Protocols	199
Study Hypothesis.....	201
Control Group.....	201
Eligibility Criteria.....	204
Assignment of Intervention.....	205
Sample Size.....	206
Endpoints.....	208
Blinding (Masking)	210
Comparability of Patients in Study Groups	211
Other Design Considerations.....	211
Study Data Analysis	212
Study Conduct	213
Good Clinical Practices	214
Clinical Trials, FDAMA, and FDAAA	216
FDAMA and Alternative Study Designs	216
Least Burdensome Mandate and PMAs	217
Least Burdensome Mandate and 510(k)s	218
Clinical Trial Registry.....	219
Responsibilities of Clinical Trial Sponsors, Investigators, Monitoring Groups, IRBs, and Other Study Units.....	220
Sponsor Obligations	220
Requirements for an NSR Device	220
Requirements Prior to Clinical Trial.....	220
Requirements during a Clinical Trial.....	221

Medical Device Development: A Regulatory Overview

Requirements after Clinical Phase	221
Recordkeeping Requirements.....	222
Reporting Requirements.....	222
Investigator Obligations.....	224
Requirements Prior to Clinical Trial	224
Requirements during a Clinical Trial	224
Requirements after Clinical Phase	225
Recordkeeping Requirements.....	226
Reporting Requirements.....	226
Adverse Event Reporting	227
Financial Disclosure by Clinical Investigators	227
The Monitoring of Clinical Studies.....	229
Qualifications of a Study Monitor	229
Monitoring Procedures	230
Result of Monitoring or Failure to Monitor	232
IRB Obligations.....	232
Membership	232
Functions and Operations.....	232
Informed Consent.....	232
Continuing Review.....	233
Suspension of Approval.....	233
Other Study Units.....	233
International Clinical Studies.....	235
Data from International Feasibility Studies	235
International and U.S. Data	236
Reliance on International Data as the Sole Basis for Approval	237

Chapter 7 The Premarket Approval Application.....	239
Medical Devices Subject to the PMA Process	240
Early Collaboration Meetings under FDAMA	240
Structure of the PMA Application	242
Administrative Documents.....	243
Section 1: General Information.....	244
Section 2: Table of Contents	244
Section 3: Summary of Safety and Effectiveness Data.....	244
Section 4: Device Description and Manufacturing	246
Device Description.....	246
Manufacturing.....	247
Section 5: Performance Standards	248
Section 6: Technical Data.....	249
Preclinical Studies.....	249
Clinical Studies.....	250
Section 7: Justification for One Investigator	251
Section 8: Bibliography, References, and Other Reports	252
Section 9: Samples	252
Section 10: Labeling.....	252
Section 11: Environmental Assessment	252
Section 12: Financial Certification or Disclosure Statement.....	253
Common Flaws in Drafting PMAs.....	253
Biostatistical Methodologies and Analyses Supporting PMA Approval	255
Statistical and Data Presentation.....	255
Common Deficiencies	256
Patient Accountability	256
Protocol Not Followed.....	257
Hypothesis Test Not Stated or Performed.....	257
Insufficient Justification for Pooling.....	257
Potential Bias Not Evaluated.....	257

Table of Contents

Sample Size Not Justified.....	257
The Modular PMA Review.....	258
Chapter 8 Review of a Premarket Approval Application.....	263
Overview of the PMA Review Process.....	263
The Filing Decision.....	264
Expedited Review of PMAs.....	268
FDA Review of the PMA Application.....	269
The Day-100 Meeting and Other Mid-Review Communications.....	270
A Modular Approach to PMA Review.....	272
The Panel Review Process.....	272
Advisory Panel Member Selection.....	274
Advisory Panel Procedures.....	277
Preparing for Advisory Panel Presentations.....	278
Providing New Information during the PMA Review Process:	
Amendments to Pending PMAs.....	282
PMA Amendments and Resubmitted PMAs.....	282
Voluntary Withdrawal of a PMA.....	283
FDA Action on a PMA.....	284
PMA Submission and Approval Times.....	286
PMA Confidentiality during the Review Process.....	287
Conditions of PMA Approval: Quality System Regulation (QSR)	
Inspections and Bioresearch Monitoring.....	288
QSR Inspections.....	288
Bioresearch Monitoring Inspections.....	290
Postapproval Requirements.....	291
Postmarket Surveillance Studies.....	294
Withdrawal of a PMA Approval.....	295
Change of PMA Ownership.....	296
Chapter 9 PMA Supplements.....	297
When is a PMAS Necessary and What Type Should be Submitted?.....	298
Traditional PMA.....	301
Panel-Track Supplement.....	301
180-Day Supplement.....	302
Real-Time Supplement.....	303
Special PMA Supplement—Changes Being Effected.....	303
The 30-Day Notice and 135-Day Supplement.....	304
The 30-Day Supplement.....	306
PMA Supplement—Manufacturing Site Change.....	306
Periodic Reports (“Annual Reports”).....	307
The PMA Supplement Application.....	309
Review of the PMA Supplements.....	310
PMA Supplement Strategies.....	311
Chapter 10 Medical Device Reclassification.....	313
Reclassification Standard.....	314
The Statutory Framework.....	316
Reclassification Based on New Information.....	316
Reclassification Based on FDA’s Requirement for Performance	
Standards/Premarket Approval.....	317
Reclassification of New Devices.....	318
Reclassification of Transitional Devices Under the 1976 Amendments....	321
The Reclassification of Preamendment Class III Devices.....	324
Data Requirements for the Reclassification Petition.....	327

Medical Device Development: A Regulatory Overview

FDA's Reclassification Record, 1976-2008.....	329
Contact Lenses	329
Sutures	331
Drionic Device	333
Inductive Nasal Device.....	333
Magnetic Resonance Imaging.....	334
Ophthalmic Nd:Yag Lasers.....	334
Automated Differential Cell Counter.....	335
Obstetrics and Gynecology Devices.....	335
Endosseous Dental Implants.....	336
Pedicule Screw Spinal Systems	336
Bone Sonometers	337
Cutaneous Electrodes.....	338
Intervertebral Body Fusion Devices.....	338
Absorbable Hemostatic Agent and Dressings.....	338
De Novo Classification.....	339
Influenza A IVD and Cancer Molecular Expression Test.....	340
Conclusion	341

Chapter 11 The Regulation of In Vitro Diagnostics

FDA Regulation of IVDs.....	343
CBER Regulation of IVDs	344
CDRH Regulation of IVDs	345
Labeling of IVDs	346
RUO and IUO Devices.....	346
Labeling of Cleared/Approved IVDs.....	346
Clinical Investigations Involving IVDs	348
IVD Exemption from IDE Regulation	348
IRB and Informed Consent Requirements.....	351
Analytical Studies and Reagent Characterization.....	353
Reagent Characterization & Interference Studies.....	353
Performance Characteristics Testing.....	354
Analytical Sensitivity or Limit of Detection Studies.....	354
Precision or Reproducibility Studies	354
Accuracy Studies	355
Linearity Studies	355
Special Topics.....	356
Analyte Specific Reagents, General Purpose Reagents, and Laboratory Developed Tests.....	356
IVD Automation	360
CLIA Categorization and Waivers.....	361
Personalized Medicine and Companion Diagnostics.....	363

Chapter 12 The Quality System Regulation.....

Scope of the QSR.....	368
Management Responsibility.....	370
Quality Policy.....	371
Organization.....	371
Management Representative.....	372
Management Review.....	373
Quality Planning	374
Quality Procedures	374
Quality Audits.....	374
Personnel (and Training)	376
Design Controls.....	376
Design and Development Planning	377

Table of Contents

Design Inputs.....	377
Design Outputs.....	378
Design Verification and Validation.....	378
Design Review.....	379
Design Transfer.....	379
Recordkeeping.....	380
Purchasing Controls.....	380
Supplier Evaluation.....	381
Supplier Control.....	382
Recordkeeping.....	382
Purchasing Data.....	382
Incoming Inspection Activities.....	383
Production and Process Controls.....	383
Production and Process Changes.....	384
Environmental Control.....	384
Personnel.....	385
Contamination Control.....	385
Buildings.....	386
Equipment.....	386
Automated Processes.....	386
Process Validation.....	387
Monitoring.....	388
Receiving, In-Process, and Finished Device Acceptance.....	389
Incoming Acceptance Activities.....	389
In-Process Acceptance Activities.....	389
Final Acceptance Activities.....	389
Recordkeeping Requirements.....	390
Nonconforming Product.....	390
Corrective and Preventive Action (CAPA).....	391
Device Recordkeeping.....	392
Device Master Record.....	393
Device History Record.....	394
Complaint Handling.....	394
Servicing.....	395
Statistical Techniques.....	395
Conclusion.....	396

Chapter 13 Compliance.....	397
Establishment Registration and Device Listing.....	397
Initial Registration and Listing.....	397
Annual Certification.....	400
User Fees.....	401
Updating Information.....	401
Foreign Facilities.....	401
Misbranding by Reference to Establishment Registration.....	402
Medical Device Reporting.....	402
Manufacturers and MDR Reporting Requirements.....	403
Device Manufacturers and MDR-Reportable Events.....	403
Time and Knowledge Requirements.....	405
Importers and MDR Reporting Requirements.....	406
Importers and MDR-Reportable Events.....	406
Time and Knowledge Requirements.....	407
User Facilities and MDR Reporting Requirements.....	407
MDR-Reportable Events.....	408
Time and Knowledge Requirements.....	408
Sentinel Reporting System.....	409
The Practical Application of the MDR.....	409

Medical Device Development: A Regulatory Overview

Internal MDR Procedures	409
Recordkeeping Requirements	410
How and Where to File.....	410
When Not to File.....	410
Enforcement Actions	411
Recall Policy, Procedures, and Industry Responsibilities— Reports of	
Corrections and Removals	411
Voluntary Recalls	412
Health Hazard Evaluations.....	412
Recall Strategy.....	413
Recall Classification	414
FDA Notice under Part 7	415
Recall Communications.....	415
Recall Status Reports	416
Recall Termination.....	416
Reporting to FDA under Part 806.....	416
Reportability of Recalls that Occur Exclusively Outside of the U.S.	419
FDA Mandated Recalls	420
Strategy for Compliance with Order.....	421
Termination of Order	421
Advertising and Promotion.....	422
Regulatory Authority	422
Labels, Labeling, and Intended Use	423
Labels.....	423
Labeling.....	423
Prescription Devices.....	423
Restricted Devices.....	424
Intended Use and Indications for Use	424
Adulteration and Misbranding Provisions Applicable to Advertising,	
Labeling, and Promotion.....	424
Misbranding.....	425
Misbranding and Adulteration for Lack of Clearance or Approval	425
False and Misleading Statements.....	426
General Versus Specific Claims.....	426
Regulatory Status.....	426
Comparative Claims.....	427
Off-Label Promotion	427
Off-Label Device Promotion Precedent from Drug Regulation	428
Dissemination of Off-Label Scientific and Medical Information	431
Enforcement Provisions	431
Inspections.....	432
Warning Letters and Untitled Letters.....	432
Administrative Detention.....	433
Recalls (Voluntary and Mandatory) I.....	433
Application Integrity Policy (AIP).....	433
Injunctions, Preliminary Injunctions, and Consent Decrees	434
Refusing Requests for Premarket Approval (PMA) of New Products/	
PMA Suspensions.....	435
Civil Penalties	435
Combined Civil and Criminal Actions	437
Conclusion	438
Chapter 14 Medical Device Exports and Imports.....	439
Export of Legally Marketed Devices	439
Export of Unapproved or Uncleared Devices.....	440
Exporting Uncleared Devices Due to Lack of 510(k) Marketing	
Clearance—Section 801(e)(1)	441

Table of Contents

Exporting Medical Devices via Section 801(e)(2).....	442
Exporting Medical Devices via Section 802.....	444
Exporting for Investigational Use.....	446
Exporting for Marketing or in Anticipation of Foreign Market Approval.....	447
Importing for Export.....	448
Certificates of Exportability.....	449
Certificates to Foreign Governments.....	449
Certificates of Exportability.....	450
Importation of Medical Devices.....	450
Entry Requirements.....	450
FDA Regulatory Requirements Applicable to Initial Importers.....	451
Inter-Agency Guidance on Good Importer Practices.....	452
Chapter 15 Product Jurisdiction and the Regulation of Combination Products.....	455
Introduction.....	455
Combination Products.....	465
Determining Primary Jurisdiction for a Combination Product.....	465
FDA Intercenter Agreements.....	468
Request for Primary Jurisdiction Designation.....	469
Strategies for Combination Product Approval.....	471
Single Entity Products.....	473
Good Manufacturing Practices for Combination and Single Entity Products.....	474
Conclusion.....	475
Chapter 16 Working Well with FDA.....	477
Frequent Communication.....	477
Internal Planning for the Product Submission.....	478
Meeting with CDRH.....	478
Review Status Reports.....	480
Disagreements between CDRH and the Sponsor.....	481
Truthful and Accurate Communication.....	484
Strategies for Successful Product Submissions.....	485
Glossary.....	489
Index.....	511